Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk  by von Eckardstein, Arnold et al.
Lipoprotein(a) Further Increases the Risk of Coronary
Events in Men With High Global Cardiovascular Risk
Arnold von Eckardstein, MD,* Helmut Schulte, PHD,† Paul Cullen, MD, FRCP,*
Gerd Assmann, MD, FRCP*†
Mu¨nster, Germany
OBJECTIVES This prospective population study was conducted to assess the role of elevated lipoprotein(a)
[Lp(a)] as a coronary risk factor.
BACKGROUND The role of elevated Lp(a) as a risk factor for coronary heart disease is controversial. In
addition, little attention has been paid to the interaction of Lp(a) with other risk factors.
METHODS A total of 788 male participants of the Prospective Cardiovascular Mu¨nster (PROCAM)
study aged 35 to 65 years were followed for 10 years. Both Lp(a) and traditional
cardiovascular risk factors (e.g., age, low density lipoprotein [LDL] cholesterol, high density
lipoprotein [HDL] cholesterol, triglycerides, systolic blood pressure, cigarette smoking,
diabetes mellitus, angina pectoris, and family history of myocardial infarction) were evaluated
in 44 men who suffered from myocardial infarction, and in 744 men who survived without
major coronary events or stroke. A multiple logistic function algorithm was used to estimate
global cardiovascular risk by the combined effects of traditional risk factors.
RESULTS Overall, the risk of a coronary event in men with an Lp(a) $0.2 g/liter was 2.7 times that of
men with lower levels (95% confidence interval [CI]: 1.4 to 5.2). This increase in risk was
most prominent in men with LDL cholesterol level $4.1 mmol/liter (relative risk [RR]: 2.6;
95% CI: 1.2 to 5.7), with HDL cholesterol #0.9 mmol/liter (RR 8.3; 95% CI: 2.0 to 35.5),
with hypertension (RR 3.2; 95% CI: 1.4 to 7.2), or within the two highest global risk quintiles
(relative risk: 2.7; 95% CI: 1.3 to 5.7).
CONCLUSIONS Lp(a) increases the coronary risk, especially in men with high LDL cholesterol, low HDL
cholesterol, hypertension and/or high global cardiovascular risk. (J Am Coll Cardiol 2001;37:
434–9) © 2001 by the American College of Cardiology
Coronary heart disease (CHD) is multifactorial in origin. In
addition to the traditional risk factors, which include age,
male gender, smoking, diabetes mellitus, dyslipidemia, and
hypertension, a series of novel risk factors have been
identified in prospective population studies—for example,
lipoprotein(a), homocysteine, fibrinogen or C-reactive pro-
tein (1,2). Because cardiovascular risk factors interact with
one another, an individual’s risk of coronary events such as
myocardial infarction or coronary death can best be pre-
dicted by combining the information from single risk factors
using mathematical algorithms (1,3,4). Several algorithms
have been deduced using “traditional” risk factors, but the
interaction of novel risk factors with traditional risk factors
or with global risk estimates has been little investigated.
One important novel risk factor is lipoprotein(a) (Lp[a]),
a cholesteryl ester- and apolipoprotein (apo) B-containing
particle, which differs from low density lipoprotein (LDL)
by the additional presence of a glycoprotein termed apo(a),
which is homologous to plasminogen (5,6). In vitro and in
vivo, Lp(a) has been found to exert a broad variety of
pro-atherogenic and pro-thrombotic properties (5,6). As
the clinical consequence, Lp(a) has been identified in most
but not all prospective studies as a risk factor for coronary
events (7–16).
In the Prospective Cardiovascular Mu¨nster (PROCAM)
study, 10-year follow-up data have now become available on
a cohort of 5,333 men aged 35 to 65 years at recruitment. In
a subgroup of 820 men, Lp(a) was measured in freshly
isolated serum. We have now analyzed these data to
investigate the interactions between traditional risk factors
alone and between these risk factors and Lp(a) in predicting
the occurrence of fatal or nonfatal myocardial infarction or
sudden coronary death.
METHODS
Description of the PROCAM study. The design of the
PROCAM study has been described in detail previously
(10,17). The protocol has been approved by the Ethics
Committee of the Westphalian Wilhelms-University. The
study has been performed in accordance with the standards
of the Helsinki Declaration. In brief, some 34,000 16- to
65-year-old employees of 52 companies and public author-
ities were recruited between 1979 and 1985. Examinations
were carried out during paid working hours and included
case history using standardized questionnaires, measure-
ment of body weight and height as well as blood pressure, a
resting electrocardiogram and the collection of a blood
sample after a 12-h fast for the determination of .20
laboratory parameters. All findings were reported to the
participant’s general practitioner. The investigators neither
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carried out nor arranged for any intervention (10,17). Lp(a)
was measured in a subgroup of 1,989 men and 995 women
who were recruited into the PROCAM study in 1982 and
1983.
Risk factor assessment. Glucose, total cholesterol, triglyc-
erides, and high density lipoprotein (HDL) cholesterol were
measured using the Hitachi 737 autoanalyzer, enzymatic
assays and (for HDL cholesterol) a precipitation method
from Roche Diagnostics (Mannheim, Germany). Lp(a) was
analyzed in freshly isolated sera by electroimmunodiffusion
using the IgG-fraction of specific rabbit anti-Lp(a)-antisera
from Behringwerke (Marburg, Germany) and standards
from Immuno (Vienna, Austria) (18). The interassay im-
precision for Lp(a) measurement was below 10%. Low
density lipoprotein cholesterol was calculated either by the
original Friedewald formula (19) or by a modification of the
Friedewald formula where the estimated cholesterol content
of Lp(a) (i.e., 0.0078zLp(a) in mmol/liter) was subtracted
from LDL cholesterol (20).
Anyone smoking cigarettes within the last 12 months was
considered a current smoker. A proband was considered as
hypertensive when he knew this diagnosis and was treated
with anti-hypertensive drugs or, in accordance with the
definition by the Joint National Committee (21), when
systolic and diastolic blood pressures were $140 mm Hg
and/or $90 mm Hg, respectively. A subject was defined as
affected by diabetes mellitus if this diagnosis was known to
the patient or, according to the American Diabetes Asso-
ciation definitions, if fasting glucose in the serum was $7
mmol/liter (22). A family history was considered as positive
of CHD when at least one first- or second-degree relative
had suffered from myocardial infarction before the age of 60
years (17).
Follow-up. Questionnaires were sent to the participants
every two years to determine the occurrence of myocardial
infarction, stroke or death. The response rate to these
questionnaires was 96% after an average of two reminders
per participant by mail and telephone if necessary. Hospital
and physician records of diseased or deceased probands,
death certificates as well as eyewitness accounts of deaths
were obtained and examined by a Critical Event Committee
(members: Prof. Dr. U. Gleichmann, Bad Oeynhausen;
Prof. Dr. K. Kochsiek, Wu¨rzburg; and Prof. Dr. E. Ko¨hler,
Bad Salzuflen) to verify the diagnosis or cause of death.
Nonfatal myocardial infarction, fatal myocardial infarction
and sudden cardiac death were defined as major coronary
events (MCEs) and considered as end points (10).
Statistics. An explorative analysis was performed using the
statistical package for the social sciences (SPSS-X) (23).
Comparisons between groups were done with the Mann-
Whitney U-test for continuous variables and with the
chi-square test for discrete variables. Odds ratios (ORs)
were calculated using the category with the lowest coronary
event rate as the baseline. The ORs of elevated Lp(a) in the
presence or absence of additional risk factors were compared
by logistic regression analysis (24).
The simultaneous contributions of several factors to the
risk of MCEs were analyzed by the use of a multiple logistic
function (MLF) model (10,23). This model was originally
derived from data of a population of 5,333 men aged 35 to
65 years, without a prior history of myocardial infarction or
stroke, who were followed for 10 years. Of this group, 345
men experienced a coronary event; 4,626 men survived the
10 years after initial examination without definite coronary
events or stroke. Age, blood pressure and laboratory data
were used as continuous variables, implying a dose-response
relationship to MCEs. Forward and backward selection was
used to build up the logistic regression model. Both proce-
dures were modified so that at each point of the selection
process the partial significance of each term included in, or
excluded from, the model was reviewed. An independent
parameter was defined to be associated with coronary events
if the initial probability and the partial probability value in
the presence of other variables was less than 0.05. Maximum
likelihood statistics were used for the selection process. As a
last step, interactions between the variables remaining in the
final model were tested.
RESULTS
The importance of Lp(a) as a cardiovascular risk factor was
investigated in 820 men aged between 35 and 65 years at
recruitment who were followed up for 10 years. In this
subgroup, 32 men suffered from definite nonfatal myocar-
dial infarctions and 8 others from fatal myocardial infarc-
tion. In eight other men, CHD was diagnosed but no MCE
occurred. Four sudden cardiac deaths were also recorded.
Eighteen men died from causes other than CHD. Eight
fatal and nonfatal strokes were recorded. Seven hundred and
forty-four men survived the 10 years after initial examina-
tion without nonfatal myocardial infarction or stroke.
At recruitment the 44 men with MCE1 had significantly
higher levels of cholesterol, LDL cholesterol, triglycerides,
and blood glucose, and lower levels of HDL cholesterol
than did the 744 men without coronary events or stroke
(MCE2). Systolic blood pressure was also increased in this
group (Table 1).
The 44 participants who suffered an MCE had a signif-
icantly higher median level of Lp(a) (0.09 g/liter, range: 0 to
Abbreviations and Acronyms
apo 5 apolipoprotein
BMI 5 body mass index
CHD 5 coronary heart disease
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
MCE 5 major coronary event
MLF 5 multiple logistic function
OR 5 odds ratio
PROCAM study 5 Prospective Cardiovascular Mu¨nster
study
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3.57 g/liter; p , 0.05) than did the 744 men without MCE
(0.04 g/liter, range: 0 to 0.98 g/liter). The risk of MCE did
not increase significantly within the lowest four quintiles of
Lp(a) but was significantly elevated in the highest quintile
of Lp(a)—that is, in men with an Lp(a) .0.17 g/liter (Fig.
1). This cutoff is close to the risk threshold value of 0.20
g/liter, which we have previously found in a case-control
study (19). The RR of coronary events in men with Lp(a)
$0.2 g/liter amounted to 2.7 (95% confidence interval: 1.4
to 5.2).
The effect of elevated Lp(a) on coronary risk was mod-
ulated by other risk factors (Table 2). The combination of
Lp(a) $0.2 g/liter with elevated LDL cholesterol, low
HDL cholesterol or hypertension further increased the risk
of coronary events. In men with an LDL cholesterol ,4.1
mmol/liter, HDL cholesterol ,0.9 mmol/liter, or without
hypertension, the presence of an elevated Lp(a) did not
further increase the risk of an MCE. After correction of
LDL cholesterol for Lp(a), which contributes to the LDL
cholesterol estimated by the Friedewald formula, high Lp(a)
increased cardiovascular risk in men with both normal and
low LDL cholesterol (Table 2). Surprisingly, Lp(a) levels
$0.2 g/liter increased the risk of coronary events in nor-
motriglyceridemic men and in nonsmokers but not in
hypertriglyceridemic men or smokers (Table 2). The inter-
action of elevated Lp(a) with low triglycerides also remained
stable after lowering of the triglyceride cutoff to 1.7 mmol/
liter (not shown). Elevated Lp(a) increased coronary risk in
men without angina pectoris, without diabetes mellitus or
without a family history of premature myocardial infarction.
The case numbers were too small to address the question on
the role of elevated Lp(a) in men with angina pectoris,
diabetes mellitus or with a family history of premature
myocardial infarction.
As the result of these interactions, Lp(a) $0.2 g/liter only
increased the risk of coronary events in those men, whose
coronary risk was in the top two quintiles as estimated by
MLF but not in those men whose coronary risk was within
the lowest three quintiles of global risk as estimated by
MLF (Fig. 2). It is, however, important to note that all
seven men who had an estimated risk within the lowest
three quintiles and who suffered from a coronary event
during follow-up presented with Lp(a) levels below 0.2
g/liter (Fig. 2). Other risk factors did not differ between
men with high global risk/Lp(a) ,0.2 g/liter and men with
high global risk/Lp(a) $0.2 g/liter (Table 3).
DISCUSSION
This prospective, population-based 10-year follow-up study
of 820 middle-aged men confirms and strengthens the
importance of Lp(a) as a risk factor of coronary events (10).
To our knowledge, the PROCAM study is the only
prospective population study where Lp(a) was measured in
fresh serum samples. Most prospective data on the role of
Table 1. Mean Values of Age-Standardized Factors for Men 35 to 65 Years Old With
(MCE1) and Without (MCE2) Development of MCEs Within 10 Years
Variable
MCE2
(n 5 744)
MCE1
(n 5 44)
p
Value
Age (yrs) 47.69 (7.03) 50.68 (5.89) 0.006
Cholesterol (mmol/liter) 5.82 (1.05) 6.87 (1.15) , 0.001
HDL cholesterol (mmol/liter) 1.21 (0.31) 1.11 (0.35) 0.037
LDL cholesterol (mmol/liter)* 3.80 (0.94) 4.76 (0.89) , 0.001
Triglycerides (mmol/liter)‡ 1.61 1.95 0.019
Systolic blood pressure (mm Hg) 131.6 (17.3) 138.8 (17.7) 0.008
Diastolic blood pressure (mm Hg) 87.9 (10.6) 91.0 (11.8) 0.056
Body mass index (kg/m2) 25.98 (2.93) 26.70 (2.68) 0.113
Fasting blood glucose (mmol/liter) 5.47 (0.80) 5.90 (1.75) 0.002
Lipoprotein(a) (g/liter)‡ 0.04 0.09 0.001
LDL cholesterol—Lp(a) (mmol/liter)† 3.72 (0.93) 4.53 (0.96) , 0.001
Angina pectoris (%) 1.2 6.8 0.003
Smoker (%) 22.4 45.5 , 0.001
Diabetes mellitus 3.5 4.5 0.719
Hypertension 58.9 70.5 0.129
Myocardial infarction in the family history (%) 19.1 15.9 0.601
*LDL cholesterol was determined by the Friedewald formula (19); †LDL cholesterol (Friedewald) was corrected by subtracting
0.078 Lp(a) (in g/liter); ‡Median. Values are mean and SD (in parentheses) unless otherwise indicated.
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; MCE 5 major coronary event.
Figure 1. Incidence of major coronary events in male Prospective Cardio-
vascular Mu¨nster study (PROCAM) participants aged 35 to 65 years over
a 10-year period according to quintiles of Lp(a): 44 events among 788 men.
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Lp(a) as a cardiovascular risk factor have been obtained from
population and nested case-control studies where Lp(a) was
measured in serum or plasma samples that have been stored
for several years (7–9,11–16). Because freezing and thawing
of serum interferes with the accurate measurement of Lp(a)
(25,26), this interference may be responsible for the negative
outcome of some prospective studies (13–16,24).
In this PROCAM subpopulation the average risk of a 35-
to 60-year-old man to suffer from a coronary event was 56
per 1,000 per 10 years. This incidence rate was significantly
surpassed in men with an Lp(a) level within the highest
quintile—that is, .0.17 g/liter (Fig. 1). This threshold
value is close to the cutoff of 0.2 g/liter, which we previously
found in a large case-control study (18). This cutoff was
therefore also used to study the interaction of elevated Lp(a)
with other risk factors in the determination of coronary risk
(Table 2).
In agreement with data from several prospective and
case-control studies, elevated Lp(a) aggravated the coronary
risk in men with elevated LDL cholesterol but not in men
with LDL cholesterol levels ,4.1 mmol/liter (8,9,11,15,
20,27,28) (Table 2). However, after adjustment of LDL
cholesterol for the estimated content of cholesterol in Lp(a),
this interaction disappeared. This finding is in contrast to
that of others (20,29) but suggests that some of the apparant
aggravating effect of elevated LDL cholesterol is explained
by Lp(a) itself and therefore underscores the importance of
Lp(a) as an independent risk factor.
As expected and in agreement with data from the Quebec
Cardiovascular Study (15) and the National Heart, Lung
and Blood Institute (NHLBI) Family Heart Study (29),
elevated Lp(a) increased coronary risk more profoundly in
men with hypertension or low HDL cholesterol as com-
pared to men with normal blood pressure or HDL choles-
terol. By contrast and also in light of data from the NHLBI
study (29), elevated Lp(a) had statistically significant asso-
ciations with coronary events in nonsmokers and in men
with normal triglycerides, but not in smokers or hypertri-
glyceridemic subjects. These interactions must be repro-
duced in other studies before one speculates on the meta-
bolic basis of these unexpected findings. Elevated Lp(a)
increased the coronary risk in patients without diabetes
Table 2. Relative Risk of MCEs According to Elevated Lp(a) and Other Risk Factors
Cohort
(n)
Events
(n)
RR
(95% CI)
p
Value*
Angina pectoris (no) 776 41 2.7 (1.4–5.4) 0.002
Angina pectoris (yes) 12 3 1.8 (0.1–30.8) 0.700
Nonsmokers 601 24 3.4 (1.4–8.0) 0.003
Smokers 187 20 1.8 (0.7–5.1) 0.255
Hypertension (no) 318 13 2.2 (0.6–7.3) 0.203
Hypertension (yes) 468 31 3.0 (1.4–6.6) 0.004
Diabetes mellitus (no) 757 42 3.0 (1.5–5.7) 0.001
Diabetes mellitus (yes) 28 2 0.9 (0.8–1.0) 0.549
Negative family history 639 37 2.5 (1.3–5.2) 0.009
Positive family history 149 7 3.9 (0.8–18.5) 0.070
LDL cholesterol ,4.1 mmol/liter 497 12 1.3 (0.3–6.1) 0.726
LDL cholesterol $4.1 mmol/liter 266 29 2.6 (1.2–5.7) 0.018
LDL cholesterol–Lp(a) ,4.1 mmol/liter 517 15 2.7 (0.9–8.0) 0.079
LDL cholesterol–Lp(a) $4.1 mmol/liter 235 25 2.7 (1.1–6.6) 0.028
HDL cholesterol .0.9 mmol/liter 687 35 2.1 (0.95–4.4) 0.062
HDL cholesterol #0.9 mmol/liter 101 9 8.3 (2.0–35.5) 0.001
Triglycerides #2.3 mmol/liter 593 24 3.2 (1.4–7.5) 0.005
Triglycerides .2.3 mmol/liter 195 20 2.2 (0.8–6.1) 0.138
1th–3rd MLF quintile 443 7 0.01 (0–9.4) 0.305
4th and 5th MLF quintile 318 34 2.7 (1.3–5.7) 0.006
5th MLF quintile 147 22 2.8 (1.1–7.2) 0.032
*The p value is calculated by chi-square test. Data show the relative risk (RR) of coronary events within 10 years in men 35
to 65 years old with Lp(a) $0.2 g/liter in the presence or absence of the additional risk factors. Values are mean and SD (in
parentheses) unless otherwise indicated. Differences in the odds ratio (ORs) between the pairs were not statistically significant
as calculated by logistic regression analysis (24).
CI 5 confidence interval; HDL 5 high density lipoprotein; LDL 5 low density lipoportein; MCE 5 major coronary event;
MLF 5 multiple logistic function.
Figure 2. Incidence of major coronary events in male Prospective Cardio-
vacular Mu¨nster study (PROCAM) participants aged 35 to 65 years over
a 10-year period according to risk estimated by multiple logistic function
and Lp(a): 41 events among 761 men. Lp(a) 5 lipoprotein(a); 95% CI 5
95% confidence interval.
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mellitus or without family history of premature myocardial
infarction. Because of small case numbers it is not reason-
able to make conclusions from our study on the role of
elevated Lp(a) on cardiovascular risk in subgroups of pa-
tients with angina pectoris, diabetes mellitus or a family
history positive for myocardial infarction (Table 2). Previous
studies are controversial as to whether Lp(a) increases
cardiovascular risk in diabetes mellitus (30,31).
Combination of the risk factor information by a mathe-
matical algorithm (10) allowed us to define two high-risk
quintiles of men in which no fewer than 83% of all coronary
events occurred. Lp(a) improved prediction of coronary
events, especially in men with high (i.e., 5th MLF quintile)
and moderately increased (i.e., 4th quintile of MLF) global
risk of coronary events but does not do so in men with low
estimated global coronary risk (1st to 3rd quntiles of MLF)
(Fig. 2). This finding is in agreement with those of the
NHLBI Family Heart Study, where, however, only the
number of risk factors was evaluated, but not as in our study
where the severity of multiple risk factors was evaluated
(29). These observations may also explain why Lp(a) was
found to be a risk factor of coronary events in those studies
where participants were at high risk for coronary events
(e.g., the Lipid Research Clinics Prevention Trial or the 4S
study; [8,11]) but not studies such as the Physician’s Health
study, the participants of which were at a generally low
cardiovascular risk (14).
Conclusions. Finally, in this prospective population study
of middle-aged men, elevated Lp(a) evolved as an important
independent coronary risk factor that aggravates the coro-
nary risk exerted by elevated LDL cholesterol (as estimated
by the Friedewald formula), low HDL cholesterol, hyper-
tension or the combined effects of multiple risk factors. The
Lp(a) levels are predominantly determined by genetic vari-
ation of the apo(a) gene (5,6). Except for sex steroids,
thyroid hormone and growth hormone, no drugs are known
to lower Lp(a) levels (5,6). To date it is only the HERS
study (32), which demonstrated an association between the
lowering of Lp(a) by the use of hormone replacement
therapy and the reduction of second coronary event rates in
postmenopausal women. Therefore and because Lp(a) in-
creases the risk of coronary events strongly depending on
the presence of additional coronary risk factors, it is imper-
ative to strictly control additional risk factors in individuals
with elevated Lp(a). In agreement with this concept, low-
ering of LDL cholesterol with colestipol or simvastatin was
previously found to reduce coronary events in individuals
with elevated Lp(a) (11,20).
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